

Strukturiertes Publikationsverzeichnis**Originalarbeiten:**

Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanović S, Dörfel D, Schneider P, Salih HR. Neutralization of NK cell-derived B cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

Leukemia 2015 (Epub ahead of print)

Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Brenner A, Krauter J, Ganser A, Döhner H, Döhner K. Differential impact of allelic ratio and insertion site in FLT3-ITD positive AML with respect to allogeneic hematopoietic stem cell transplantation.

Blood 2014 (Epub ahead of print)

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanovic, Stickel JS. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Leukemia 2014 (Epub ahead of print)

Steinbacher J, Baltz-Ghahremanpour K, Schmiedel BJ, Stienle A, Jung G, Kübler A, André MC, Grosse Hovest L, Salih HR.: An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.

Int J Cancer 2014 (Epub ahead of print)

Raab S, Steinbacher J, Schmiedel BJ, Kousis PC, Steinle A, Jung G, Grosse-Hovest L, Salih HR. Fc-Optimized NKG2D-Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status.

J Immunol. 193:4261-72 (2014)

Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Millsom MD, Scholl C, Fröhling S.: Requirement for CDK6 in MLL – rearranged acute myeloid leukemia.

Blood 124:13-23 (2014)

Venturelli, S., Berger, A., Weiland, T., Essmann, F., Waibel, M., Nuebling, T., Häcker, S., Schenk, M., Schulze-Osthoff K., Salih, H.R., Fulda, S., Sipos, B., Johnstone, R.W., Lauer, U.M. and Bitzer, M.: Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells.

Mol Cancer Ther. 12:2226-36 (2013)

Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S.M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H.R., Cazzola, M., Melillo, L., Carella, A.M., Brandts, C.H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M.G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk*, R.F., and Platzbecker* U. for the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA), Acute Myeloid Leukemia Study Group (AMLSG) and the German Study Alliance Leukemia (SAL): Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia.

N Engl J Med. 369:111-21. (2013)

Amadori, S., Suci, S., Stasi, R., Salih, H.R., Selleslag, D., Muus, P., de Fabritiis, P., Venditti, A., D Ho, A., Lübbert, M., Thomas, x., Latagliata, R., JM Halkes, C., Falzetti, F., Magro, D., E Guimaraes, J., Berneman, Z., Specchia, G., Karrasch, M., Fazi, P., Vignetti, M., Willemze, R., De Witte, T., and Marie, J-P.:

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17).

J Clin Oncol, 31:4424-30 (2013)

- Gaidzik, V.I., Schlenk, R.F., Paschka, P., Stoelzle, A., Spaeth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H.G., Kremers, S., Greil, R., Raghavachar, A., Ringhoffer, M., Salih, H.R., Wattad, M., Kirchen, H.G., Runde, V., Heil, G., Petzer, A.L., Girschikofsky, M., Heuser, M., Kayser, S., Göhring, G., Teleanu, M-V., Schlegelberger, B., Ganser, A., Krauter, J., Bullinger, L., Doehner, H., and Doehner, K.: Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)
Blood 121:769-77 (2013)
- Palme, D., Misovic, M., Schmid, E., Klumpp, D., Salih, H.R., Rudner, J., and Huber, S.M.: Kv3.4 potassium channel-mediated electrosignaling controls cell cycle and survival of irradiated leukemia cells
European Journal of Physiology, in press
Pflugers Arch. 465:1209-21 2013
- Schmiedel, B.J., Werner, A., Steinbacher, J., Nuebling, T., Buechele, C., Grosse-Hovest, L. and Salih, H.R.: Generation and preclinical characterization of an Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.
Mol Ther. 21:877-86 (2013)
- Schmiedel, B.J., Nuebling, T., Steinbacher, J., Malinowska, A., Wende, C.M., Azuma, M., Schneider, P., Grosse-Hovest, L. and Salih, H.R.: Receptor Activator for NF- κ B Ligand in Acute Myeloid Leukemia: Expression, Function, and Modulation of NK Cell Immunosurveillance.
J Immunol. 190:821-31 (2013)
- Schmiedel, B.J., Scheible, C.A., Nuebling, T., Kopp, H.G., Wirths, S., Azuma, M., Schneider, P., Jung, G., Grosse-Hovest, L. and Salih, H.R.: RANKL expression, function and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.
Cancer Res. 73:683-94 (2013)
- Paschka, P., Du, J., Schlenk, R.F., Gaidzik, V.I., Bullinger, L., Corbacioglu, A., Späth, D., Kayser, S., Schlegelberger, B., Krauter, J., Ganser, A., Köhne, C.H., Held, G., von Lilienfeld-Toal, M., Kirchen, H., Rummel M., Götze, K., Horst, H.A., Ringhoffer, M., Lübbert, M., Wattad, M., Salih, H.R., Kündgen, A., Döhner, H. and Döhner, K.: Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Blood. 121:170-7 (2013)
- Deschler, B., Ihorst, G., Platzbecker, U., Germing, U., März, E., de Figuerido, M, Fritzsche, K., Haas, P., Salih, H., Giagounidis, A., Selleslag, D., Labar, B., de Witte, T., Wijermans, P. and Lübbert, M.: Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.
Haematologica. 98:208-16 (2013)
- Konantz, M., Andre, M.C., Ebinger, M., Grauer, M., Wang, H., Grzywna, S., Rothfuss, O.C., Lehle, S., Kustikova, O.S., Salih, H.R., Handgretinger, R., Fend, F., Baum, C., Kanz, L., Quintanilla-Martinez, L., Schulze-Osthoff, K., Essmann, F. and Lengerke, C.: EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
Leukemia. 27:56-65 (2013)
- Hilpert, J., Grosse-Hovest, L., Grünebach, F., Buechele, C., Nuebling, T., Raum, T., Steinle, A. and Salih, H.R.: Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses.
J Immunol. 189:1360-71 (2012)
- Todenhöfer, T., Hennenlotter, J., Schmiedel, B.J., Hohneder, A., Grimm, S., Kühs, U., Salih, H.R., Bühring, H.-J., Fehm, T., Stenzl, A. and Schwentner, C.: Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases.
Prostate 73:162-8 (2013)
- Placke, T., Salih, H.R.* and Kopp, H.G.*: GITR Ligand Provided by Thrombopoietic Cells Inhibits NK Cell Antitumor Activity.
J Immunol. 189:154-60 (2012), *equal contribution

Metzelder, S., Schröder, T., Finck, A., Scholl, S., Fey, M., Kröger, M., Reiter, A., Salih, H.R., Götze, K., Heinicke, T., Stuhlmann, R., Müller, L., Giagounidis, A., Meyer, R., Brugger, W., Vöhringer, M., Ching, LY., Dreger, P., Mori, M., Basara, N., Schäfer-Eckart, K., Schultheis, B., Baldus, C., Neubauer, A., and Burchert, A.: High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia (AML) synergizes with allo-immune effects to induce sustained responses. *Leukemia*. 26:2353-9 (2012)

Hofmann, M., Große-Hovest, L., Nübling, T., Pyž, E., Bamberg, M.L., Aulwurm, A., Bühring, H.J., Schwartz, K., Haen, S.P., Schilbach, K., Rammensee, H.G., Salih, H.R. and Jung, G.: Generation, selection and preclinical characterization of an Fc-optimized FLT3-antibody for the treatment of myeloid leukemia *Leukemia*. 26 28-37 (2012)

Buechele, C., Baessler, T., Schmiedel, B.J., Schumacher, C.E., Rittig, K. and Salih, H.R.: 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. *Eur J Immunol*. 42:737-48 (2012)

Placke, T., Örgel, M., Schaller, M., Jung, G., Rammensee, H.G. Kopp, H.G. and Salih, H.R.: Platelet-derived MHC Class I confers a pseudo-normal phenotype to cancer cells that subverts the anti-tumor reactivity of natural killer immune cells. *Cancer Res*. 72:440-8 (2012)

Buechele, C., Baessler, T., Wirths, S., Schmohl, J.U., Schmiedel, B.J. and Salih, H.R.: Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). *Leukemia* 26:991-1000 (2012)

Schwarzlich, M.A., Gutknecht, M., Salih, J., Salih, H.R., Brossart, P., Rittig, S.M. and Grünebach, F.: The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. *Cancer Immunol Immunol.*, 61:193-202 (2012)

Krönke, J., Schlenk, R.F., Jensen, K.-O., Tschürtz, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Onken, S., Eiben, K., Habdank, M., Späth, D., Lübbert, M., Wattad, M., Kindler, T., Salih, H.R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H.-G., Krauter, J., Ganser, A., Göhring, G., Schlegelberger, B., Döhner, H. and Döhner, K.: Monitoring of Minimal Residual Disease in *NPM1* Mutated Acute Myeloid Leukemia: A study of the German-Austrian AML Study Group (AMLSTG). *J Clin Oncol*. 29: 2709-16 (2011)

Lübbert, M., Suci, S., Baila, L., Rüter, R., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H.R., Beeldens, F., Muus, P., Pflüger, K.-H., Coens, C., Hagemeijer, A., Schaefer, H.E., Ganser, A., Aul, C., de Witte, T., and Wijermans, P.W. on behalf of the EORTC Leukemia Group and the German MDS Study Group: Low-dose decitabine vs. Best Supportive Care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group. *J Clin Oncol*. 29: 1987-96 (2011)

Dreyssig, J., Kremser, A., Liepert, A., Grabrucker, C., Freudenreich, M., Schmid, C., Kroell, T., Scholl, N., Tischer, J., Kufner, S., Salih, H., Kolb, H.J. and Schmetzer, H.M.: Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes. *Immunotherapy*. 3:1113-24 (2011)

Brodoefel, H., Salih, H., Vogel, W., Fenchel, M., and Horger, M.J.: Therapy related Noninfectious Complications in Patients with Hematologic Malignancies: High-resolution Computed Tomography Findings. *J Thorac Imag*. 2011 Jul 26

Schmiedel, B.J., Arélin, V., Gruenebach, F., Krusch, M., Schmidt, S.M. and Salih, H.R.: Azacytidine impairs NK cell reactivity while Decitabine augments NK cell responsiveness towards stimulation. *Int J Cancer* 128: 2911-22 (2011)

Boettcher, S., Wacker, A., Moerike, K., Kopp, H.-G., Jaschonek, K., Grobosch, T., Kanz, L. and Salih, H.R.: Acquired Coagulopathy Caused by Intoxication with the Superwarfarin-Type Anticoagulant Rodenticide Flocoumafen. *Eur J Haematol* 86: 173-5 (2011)

Heise, N., Palme, D., Misovic, M., Koka, S., Rudner, J., Lang, F., Salih, H.R., Huber, S.M. and Henke, G.: Non-selective cation channel-mediated Ca²⁺-entry and activation of Ca²⁺/calmodulin-dependent kinase II contribute to G2/M cell cycle arrest and survival of irradiated leukemia cells. *Cell Physiol Biochem* 26: 597-608 (2010)

Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H.R.*, and Krusch, M.*: The BCR/ABL-inhibitors imatinib, nilotinib, and dasatinib differentially affect NK cell reactivity. *Int J Cancer* 127: 2119-28 (2010), *equal contribution

Baessler, T., Charton, J.E., Schmiedel, B.J., Grünebach, F., Krusch, M., Wacker, A., Rammensee, H.-G., and Salih, H.R.: CD137 Ligand Mediates Opposite Effects in Human and Mouse NK Cells and impairs NK cell reactivity against Human Acute Myeloid Leukemia cells. *Blood* 115: 3058-69 (2010)

Kremser, A., Loibl, J., Grabrucker, C., Liepert, A., Kroell, T., Scholl, N., Schmid, C., Tischer, J., Kufner, S., Salih, H., Kolb, H.J., and Schmetzer, H.: Dendritic cells can be successfully generated from leukemic blasts in individual patients with AML or MDS: An evaluation of different methods. *J Immunother* 33: 185-199 (2010)

Krusch, M., Salih, J., Schlicke, M., Baessler, T., Kampa, K.M., Mayer, F., and Salih, H.R.: The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect Natural Killer Cell Anti-Tumor Reactivity In Vitro. *J Immunol* 183: 8286-94 (2009)

Kopp, H.G., Placke, T. and Salih, H.R.: Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. *Cancer Res* 69: 7775-83. (2009)

Haselmayer, P., Daniel, M., Tertilt, C., Salih, H.R., Stassen, M., Schild, H. and Radsak, M.P.: Signaling Pathways of the TREM-1- and TLR4-Mediated Neutrophil Oxidative Burst. *J Innate Immun* 1:582-591 (2009) (DOI:10.1159/000231973)

Riedt, T., Ebinger, M., Salih, H.R., Tomiuk, J., Handgretinger, R., Kanz, L., Grünebach, F. and Lengerke C.: Aberrant expression of the homeobox gene CDX2 in acute lymphoblastic leukemia. *Blood* 113: 4049-51 (2009)

Scholl, N., Loibl, J., Kremser, A., Liepert, A., Grabrucker, C., Salih, H.R., Kolb, H.J. and Schmetzer, H.M.: The role of soluble and cell-surface expressed 4-1BB Ligand in patients with malignant hemopoietic disorders. *Leuk Lymphoma* 50: 427-36 (2009)

Baessler, T., Krusch, M., Schmiedel, B.J., Kloss, M., Baltz, K.M., Wacker, A., Schmetzer, H.M. and Salih, H.R.: Glucocorticoid-Induced TNFR-Related Protein (GITR) ligand subverts immunosurveillance of Acute Myeloid Leukemia in humans. *Cancer Res* 69: 1037-45 (2009)

Baltz, K.M., Krusch, M., Baessler, T., Schmiedel, B.J., Bringmann, A., Brossart, P. and Salih, H.R.: Neutralization of tumor-derived soluble Glucocorticoid-Induced TNFR- Related (GITR) ligand increases NK cell anti-tumor reactivity. *Blood* 112: 3735-43 (2008)

Kloss, M., Decker, P., Baltz, K.M., Baessler, T., Jung, G., Rammensee, H.-G., Steinle, A., Krusch, M. and Salih, H.R.: Toll-Like receptor-induced expression of the NKG2D ligand MICA on monocytes modulates their interaction with NK cells. *J Immunol* 181: 6711-9 (2008)

Armeanu, S., Krusch, M., Baltz, K.M., Thomas S. Weiss, T.S., Smirnow, I., Steinle, A., Lauer, U.M., Michael Bitzer, M. and Salih, H.R.: Direct and Natural Killer cell-mediated anti-tumor effects of low-dose Bortezomib in Hepatocellular Carcinoma. *Clin Cancer Res* 14: 3520-8 (2008)

Rittig, K., Peter, A., Baltz, K.M., Tschritter, O., Weigert, C., Andreozzi, F., Perticone, F., Siegel-Axel, D.I., Stefan, N., Fritsche, A., Salih, H.R., Schleicher, E., Machicao, F., Sesti, G., Häring, H.U. and Balletshofer, B.M.: The CCR2 promoter polymorphism T-960A, but not the serum MCP-1 level, is associated with endothelial function in prediabetic individuals.

Atherosclerosis 198:338-46 (2008)

Radsak, M.P., Taube, C., Haselmayer, P., Tenzer, S., Salih, H.R., Wiewrodt, R., Buhl, R. and Schild, H.-J.: Soluble Triggering Receptor expressed on myeloid Cells 1 (TREM-1) is released in patients with stable chronic obstructive pulmonary disease.

Clin Dev Immunol Article ID 52040 (2007)

Holdenrieder, S., Eichhorn, P., Beuers, U., Samtleben, W., Stieber, P., Nagel, D., Peterfi, A., Steinle, A. and Salih, H.R.: Soluble NKG2D Ligands in Hepatic Autoimmune Diseases and in Benign Diseases Involved in Marker Metabolism.

Anticancer Res 27 (4A): 2041-45 (2007)

Baltz, K.M., Krusch, M., Bringmann, A., Brossart, P., Mayer, F., Kloss, M., Baessler, T., Kumbier, I., Peterfi, A., Kupka, S., Kroeber, S., Menzel, D., Radsak, M.P., Rammensee, H.-G. and Salih, H.R.: Cancer Immunoediting by GITR (Glucocorticoid-Induced TNF Related Protein) Ligand in Humans: NK Cell / Tumor Cell Interactions.

FASEB J 21: 2442-54 (2007)

Epling-Burnette, P.K., Bai, F., Painter, J.S., Rollison, D., Salih, H.R., Krusch, M., Zou, J.X., Ku, E., Zhong, B., Boulware, D., Moscinski, L., Wei, S., Djeu, J.Y. and List, A.F.: Reduced Natural Killer (NK) Function Associated With High Risk Myelodysplastic Syndrome (MDS) and Reduced Expression of Activating NK Receptors.

Blood 109: 4816-24 (2007)

Salih, H.R., Wintterle, S., Krusch, M., Kroner, K., Chen, L. and Wiendl, H.: The Role Of Leukemia Derived B7-H1 (PD-L1) In Tumor-T-Cell Interactions In Humans.

Exp Hematol 34: 888-94 (2006)

Hentschel, N., M. Krusch, M., Kiener, P.A., Salih, H.R.* and Schmetzer, H.M.*: Serum Levels of sCD137 (4-1BB) Ligand are Prognostic Factors for Progression in Acute Myeloid Leukemia but not in Non-Hodgkin-Lymphoma.

Eur J Haematol 77:91-101 (2006) * contributed equally

Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A. and Salih, H.R.: Soluble MICB in malignant diseases: Diagnostic significance and correlation with soluble MICA.

Cancer Immunol Immun 55:1584-9 (2006)

Salih, H.R., Goehlsdorf, D. and Steinle, A: Release of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer Patients.

Hum Immunol 67: 188-95 (2006)

Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A. and Salih, H.R.: Soluble MICA in malignant diseases.

Int J Cancer 118: 684-7 (2006)

Armeanu, S., Bitzer, M., Lauer, U.M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., Steinle, A., and Salih, H.R.: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

Cancer Res 65: 6321-9 (2005)

Kufner, S., Fleischer, R.P., Kroell, T., Schmid, C., Zitzelsberger, H., Salih, H., Valle F.D., Treder, W. and Schmetzer, H.M.: Serum-free Generation and Quantification of Functionally Active Leukemia-derived DC is Possible from Malignant Blasts in Acute Myeloid Leukemia (AML) and MDS.

Cancer Immunol Immun 54: 953-70 (2005)

Radsak, M.P., Salih, H.R., Rammensee, H.-G. and Schild, H.-J.: Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: Differential regulation of activation and survival.

J Immunol 172(8) 4956-63 (2004)

- Salih, H.R., Nüssler, V., Starling, G.C., Denzlinger, C., Kiener, P.A. and Schmetzer, H.M.: Serum levels of CD137 Ligand (CD137L) and CD178 are Prognostic Factors for Progression of Myelodysplastic Syndrome.
Leuk Lymphoma 45(2) 301-8 (2004)
- Salih, H.R., Antropius, H., Gieseke, F., Lutz, S.Z., Kanz, L., Rammensee, H.-G. and Steinle A.: Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
Blood 102(4):1389-96 (2003)
- Salih, H.R., Rammensee, H.-G. and Steinle, A.: *Cutting Edge*: Down-regulation of MICA on human tumors by proteolytic shedding.
J Immunol 169: 4098-102 (2002)
- Radsak, M.P., Salih, H.R., Söckler, M, Kanz, L. and Denzlinger, C.: Sustained complete remission of recurrent acute myeloid leukemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintainance.
Leukemia 16: 1870-1 (2002)
- Salih, H.R., Starling, G.C., Brandl, S., Pelka-Fleischer, R., Haferlach, T., Kiener, P.A. and Nüssler, V.: Differentiation of Promyelocytic Leukemia: Alterations in Fas (CD95/Apo-1) and Fas Ligand (CD178) Expression.
Br J Haematol 117: 76-85 (2002)
- Knauff, M., Mulack, T., Kassubek, J., Salih, H.R. and Greenlee, M.W.: Spatial Imagery in Deductive Reasoning: a functional MRI Study.
Brain Res Cogn Brain Res 13: 203-12 (2002)
- Salih, H.R., Schmetzer, H.M., Burke, C., Starling, G.C, Dunn, R., Pelka-Fleischer, R., Nüssler V. and Kiener, P.A.: Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.
J Immunol 167: 4059-66 (2001)
- Salih, H.R., Starling, G.C., Knauff, M., Davis, P.M., Pitts, W.J., Aruffo, A. and Kiener, P.A.: Retinoic Acid and Vitamin E Modulate Expression and Release of CD178 in Carcinoma Cells: Consequences for Induction of Apoptosis in CD95 Sensitive Cells.
Exp Cell Res 270: 248-58 (2001)
- Salih, H.R., Kosowski, S.G., Haluska, V.F., Starling, G.C., Loo, D.T., Lee, F., Aruffo, A.A., Trail, P.A. and Kiener, P.A.: Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.
J Immunol 165(5): 2903-10 (2000)
- Salih, H. R., Husfeld, L. and Adam, D.: Simultaneous cytofluorometric measurement of phagocytosis, burst production and killing of human phagocytes using *Candida albicans* and *Staphylococcus aureus* as target organisms.
Clin Microbiol Infect 6: 251-8 (2000)
- Pfossier, A., Brandl, M., Salih, H., Grosse-Hovest, L. and Jung, G.: The role of the target antigen in bispecific antibody mediated killing of human glioblastoma cells: a preclinical study.
Int J Cancer 80 (4): 612-6 (1999)
- Salih, H., Husfeld, L. and Adam, D.: Inhibitory effect of heparin on neutrophil phagocytosis and burstproduction using a new whole-blood cytofluorometric method for determination.
Eur J Med Res 2, 507-13 (1997)

Review Artikel:

Schmiedel, B.J., Grosse-Hovest, L. and Salih, H.R.: A "vicious cycle" of NK cell immune evasion in AML mediated by RANKL?

Oncoimmunology, 2013 May 1;2(5):e23850

Placke T, Kopp HG and Salih HR.: The wolf in sheep's clothing: Platelet-derived "pseudo self" impairs cancer cell "missing self" recognition by NK cells.

Oncoimmunology. 2012 Jul 1;1(4):557-559.

Haen, S.P., Pereira, P.L. and Salih, H.R., Rammensee; H.-G., and Gouttefangeas, C.: More than just Tumor Destruction – Immunomodulation by Thermal Ablation of Cancer

Clin Dev Immunol. Article ID 160250 (2011)

Krusch, M. and Salih, H.R.: Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity.

Curr Med Chem. 2011 ;18(34):5174-84. (2011)

Placke, T., Kopp, H.G. and Salih, H.R. Modulation of natural killer cell anti-tumor reactivity by platelets.

J Innate Immun. 3:374-82.(2011)

Placke, T., Kopp, H.G. and Salih, H.R.: Glucocorticoid-Induced TNFR-Related (GITR) Protein and its Ligand in Anti-Tumor Immunity: Functional Role and Therapeutic Modulation.

Clin Dev Immunol. Article ID 239083 (2010)

Salih, H.R. and Steinle, A.: Reinforcing Natural Killers

Blood 113:6042-43 (2009)

Salih, H.R., Holdenrieder, S. and Steinle, A.: Soluble NKG2D ligands: prevalence, release, and functional impact.

Front Biosci 13:3448-56 (2008)

Salih, H.R. and Hartmann, J.T.: Neuro-Endocrine Tumors of the Gastrointestinal Tract: Epidemiology, Classification, Prognosis and Therapeutic Modalities.

Schweiz Rundsch Med Prax 94: 291-302 (2005)

Salih, H.R. and Kiener, P.A.: Alterations in Fas (CD 95/Apo-1) and Fas Ligand (CD178) Expression in Acute Promyelocytic Leukemia during Treatment with ATRA.

Leuk Lymphoma 45(1) 55-9 (2004)

Salih, H.R., Kiener, P.A. and Nuessler, V.: 4-1BB Ligand-Just Another Costimulating Molecule?

J Clin Pharmacol Ther 40: 348-53 (2002)('JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS')

Salih, H.R. and Nüssler, V.: Commentary: Immune Escape versus Tumor Tolerance: How do Tumors evade Immune Surveillance?

Eur J Med Res 6: 1-10 (2001)